Lung Cancer Diagnostic And Screening Global Market Report 2023

Description

“Lung Cancer Diagnostic And Screening Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lung cancer diagnostic and screening market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lung cancer diagnostic and screening? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The lung cancer diagnostic and screening market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Product: Instruments; Consumables And Accessories
2) By Test: Biomarkers Tests; Imaging Test; Biopsy; Blood Test; Other Tests
3) By Cancer Type: Non-Small Cell Lung Cancer; Small Cell Lung Cancer
4) By End User: Hospital; Independent Diagnostic Laboratories; Diagnostic Imaging Centers; Cancer Research Institutes; Other End-Users
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Bristol-Myers Squibb Company; Thermo Fisher Scientific Inc.; AstraZeneca Plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the lung cancer diagnostic and screening market are: Pfizer Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories Inc., Medtronic Plc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetic Laboratories Inc., NeoGenomics Laboratories Inc., Canon Medical Systems Corporation, Eon Health Inc., OncimmuneHoldings Plc, Broncus Medical Inc., OncoCyte, Riverain Technologies LLC, VisionGate, Foundation Medicine Inc., Biodesix, and iDNA.

The global lung cancer diagnostic and screening market is expected to grow from $1.91 billion in 2022 to $2.11 billion in 2023 at a compound annual growth rate (CAGR) of 10.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The lung cancer diagnostic and screening market is expected to reach $3.02 billion in 2027 at a CAGR of 9.4%.

The lung cancer diagnosis and screening market consists of revenues earned by entities by providing positron emission tomography (PET) scanners, and bronchoscopy. The market value includes the value of related goods sold by the service provider or included within the service offering. The lung cancer diagnosis and screening market also includes sales of products such as liquid biopsy kits, molecular testing kits, and biopsy tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Lung cancer diagnosis and screening refers to using examinations and techniques to discover and identify lung cancer in people with the goal of early detection and precise diagnosis for efficient treatment planning. It is commonly used to treat squamous cell carcinomas, adenocarcinoma, and large cell carcinoma.

North America was the largest region in the lung cancer diagnostic and screening market in 2022. The regions covered in lung cancer diagnosis and screening report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main products of lung cancer diagnostics and screening are instruments, consumables, and accessories. An instrument refers to products that are used to read or analyze the results of a diagnostic product, and process samples for a diagnostic product. The various tests include biomarkers tests, imaging tests, biopsy, blood tests, and others used for various cancer types such as non-small cell lung cancer, and small cell lung cancer. These are used by various end-users such as hospitals, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others.

The increasing prevalence of lung cancer is expected to propel the growth of the lung cancer diagnostic and screening market going forward. Lung cancer is a malignant disease with symptoms such as coughing, chest pain, and difficulty breathing that is defined by the unchecked proliferation of abnormal cells in the lung tissues. Lung cancer diagnosis and screening help lung cancer patients early diagnose the disease with various tests, including an incisional biopsy and a bronchoscopy. For instance, in January 2023, according to the American Cancer Society, a US-based government organization, in the United States, there were approximately 238,340 new cases of lung cancer (117,550 in men and 120,790 in women). Further, there were reportedly 127,070 deaths from lung cancer (67,160 in men and 59,910 in women). Therefore, the rise in the prevalence of lung cancer is driving the growth of the lung cancer diagnostic and screening market.

Technological innovations are a key trend gaining popularity in the lung cancer diagnostics and screening market. Major companies operating in the lung cancer diagnostics and screening market are introducing innovative technologies to sustain their position in the market. For instance, in December 2021, Auris Health, a US-based robotic medical company, introduced the MONARCH Robotic-Assisted Bronchoscopy procedure, the first MONARCH procedure. This procedure allows physicians to accurately diagnose small and hard-to-reach lung nodules, which enables biopsy for early diagnosis and treatment of lung disease.

In January 2022, RadNet Inc., a US-based radiology company, acquired Aidence BV for an undisclosed amount. The acquisition is expected to enhance RadNet Inc.'s leadership in developing and deploying AI to improve patient care and health and accelerate growth and innovation pipeline to provide automated and integrated AI oncology solutions for clinicians. Aidence BV is a Netherlands-based healthcare technology company focusing on clinical solutions for lung cancer screening and pulmonary nodule treatment.

The countries covered in the lung cancer diagnosis and screening market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The lung cancer diagnostics and screening market research report are one of a series of new reports from The Business Research Company that provides lung cancer diagnostics and screening market statistics, including lung cancer diagnostics and screening industry global market size, regional shares, competitors with a lung cancer diagnostics and screening market share, detailed lung cancer diagnostics and screening market segments, market trends and opportunities, and any further data you may need to thrive in the lung cancer diagnostics and screening industry. This lung cancer diagnostics and screening market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Product Code: r8138

1. Executive Summary

2. Lung Cancer Diagnostic And Screening Market Characteristics

3. Lung Cancer Diagnostic And Screening Market Trends And Strategies

4. Lung Cancer Diagnostic And Screening Market - Macro Economic Scenario

4.1. Impact Of High Inflation On Online Therapy Services Market
4.2. Ukraine-Russia War Impact On Online Therapy Services Market
4.3. COVID-19 Impact On Online Therapy Services Market
5.1. Global Lung Cancer Diagnostic And Screening Historic Market Size and Growth, 2017 - 2022, Value ($ Billion)
5.2. Global Lung Cancer Diagnostic And Screening Forecast Market Size and Growth, 2022 - 2027, 2032F, Value ($ Billion)
5.3. Global Lung Cancer Diagnostic And Screening Market Drivers and Restraints
- 5.3.1. Drivers Of The Market
- 5.3.2. Restraints Of The Market

6. Lung Cancer Diagnostic And Screening Market Segmentation

6.1. Global Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Instruments
Consumables And Accessories
6.2. Global Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Biomarkers Tests
Imaging Test
Biopsy
Blood Test
Other Tests
6.3. Global Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
6.4. Global Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Hospital
Independent Diagnostic Laboratories
Diagnostic Imaging Centers
Cancer Research Institutes
Other End-Users

7. Lung Cancer Diagnostic And Screening Market Regional And Country Analysis

7.1. Global Lung Cancer Diagnostic And Screening Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global Lung Cancer Diagnostic And Screening Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific Lung Cancer Diagnostic And Screening Market

8.1. Asia-Pacific Lung Cancer Diagnostic And Screening Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
8.3. Asia-Pacific Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
8.4. Asia-Pacific Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China Lung Cancer Diagnostic And Screening Market

9.1. China Lung Cancer Diagnostic And Screening Market Overview
9.2. China Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
9.3. China Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
9.4. China Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India Lung Cancer Diagnostic And Screening Market

10.1. India Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
10.2. India Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
10.3. India Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan Lung Cancer Diagnostic And Screening Market

11.1. Japan Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
11.2. Japan Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
11.3. Japan Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia Lung Cancer Diagnostic And Screening Market

12.1. Australia Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
12.2. Australia Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
12.3. Australia Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia Lung Cancer Diagnostic And Screening Market

13.1. Indonesia Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
13.2. Indonesia Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
13.3. Indonesia Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea Lung Cancer Diagnostic And Screening Market

14.1. South Korea Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
14.2. South Korea Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
14.3. South Korea Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe Lung Cancer Diagnostic And Screening Market

15.1. Western Europe Lung Cancer Diagnostic And Screening Market Overview
15.2. Western Europe Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
15.3. Western Europe Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
15.4. Western Europe Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK Lung Cancer Diagnostic And Screening Market

16.1. UK Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
16.2. UK Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
16.3. UK Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany Lung Cancer Diagnostic And Screening Market

17.1. Germany Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
17.2. Germany Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
17.3. Germany Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France Lung Cancer Diagnostic And Screening Market

18.1. France Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
18.2. France Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
18.3. France Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Italy Lung Cancer Diagnostic And Screening Market

19.1. Italy Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
19.2. Italy Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
19.3. Italy Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Spain Lung Cancer Diagnostic And Screening Market

20.1. Spain Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
20.2. Spain Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
20.3. Spain Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. Eastern Europe Lung Cancer Diagnostic And Screening Market

21.1. Eastern Europe Lung Cancer Diagnostic And Screening Market Overview
21.2. Eastern Europe Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
21.3. Eastern Europe Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
21.4. Eastern Europe Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. Russia Lung Cancer Diagnostic And Screening Market

22.1. Russia Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
22.2. Russia Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
22.3. Russia Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. North America Lung Cancer Diagnostic And Screening Market

23.1. North America Lung Cancer Diagnostic And Screening Market Overview
23.2. North America Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
23.3. North America Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
23.4. North America Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. USA Lung Cancer Diagnostic And Screening Market

24.1. USA Lung Cancer Diagnostic And Screening Market Overview
24.2. USA Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
24.3. USA Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
24.4. USA Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Canada Lung Cancer Diagnostic And Screening Market

25.1. Canada Lung Cancer Diagnostic And Screening Market Overview
25.2. Canada Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
25.3. Canada Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
25.4. Canada Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. South America Lung Cancer Diagnostic And Screening Market

26.1. South America Lung Cancer Diagnostic And Screening Market Overview
26.2. South America Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
26.3. South America Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
26.4. South America Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. Brazil Lung Cancer Diagnostic And Screening Market

27.1. Brazil Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
27.2. Brazil Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
27.3. Brazil Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

28. Middle East Lung Cancer Diagnostic And Screening Market

28.1. Middle East Lung Cancer Diagnostic And Screening Market Overview
28.2. Middle East Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
28.3. Middle East Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
28.4. Middle East Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

29. Africa Lung Cancer Diagnostic And Screening Market

29.1. Africa Lung Cancer Diagnostic And Screening Market Overview
29.2. Africa Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
29.3. Africa Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
29.4. Africa Lung Cancer Diagnostic And Screening Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

30. Lung Cancer Diagnostic And Screening Market Competitive Landscape And Company Profiles

30.1. Lung Cancer Diagnostic And Screening Market Competitive Landscape
30.2. Lung Cancer Diagnostic And Screening Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. F. Hoffmann-La Roche AG
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Bristol-Myers Squibb Company
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Thermo Fisher Scientific Inc.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. AstraZeneca Plc
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Lung Cancer Diagnostic And Screening Market Other Major And Innovative Companies

31.1. Abbott Laboratories Inc.
31.2. Medtronic Plc.
31.3. Danaher Corporation
31.4. Siemens Healthcare GmbH
31.5. FUJIFILM Corporation
31.6. Koninklijke Philips N.V.
31.7. GE Healthcare Bio Sciences AB
31.8. Quest Diagnostics Incorporated
31.9. Agilent Technologies Inc.
31.10. Illumina Inc.
31.11. Qiagen Inc.
31.12. Myriad Genetic Laboratories Inc.
31.13. NeoGenomics Laboratories Inc.
31.14. Canon Medical Systems Corporation
31.15. Eon Health Inc.

32. Global Lung Cancer Diagnostic And Screening Market Competitive Benchmarking

33. Global Lung Cancer Diagnostic And Screening Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Lung Cancer Diagnostic And Screening Market

35. Lung Cancer Diagnostic And Screening Market Future Outlook and Potential Analysis

35.1 Lung Cancer Diagnostic And Screening Market In 2027 - Countries Offering Most New Opportunities
35.2 Lung Cancer Diagnostic And Screening Market In 2027 - Segments Offering Most New Opportunities
35.3 Lung Cancer Diagnostic And Screening Market In 2027 - Growth Strategies
35.3.1 Market Trend Based Strategies
35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer